|   | | | |
Location:检索结果
专利查询
 
生物制剂 Biologic agents
  检索记录: 2728   总页数: 55   用时: 0.032秒
授权号 公开日 国际主分类 美国主分类 申请人 发明人 优先权
  
 每页条数 50 100 200    9 3 4 :      跳至 页           返回
全部    个人申请    机构申请    跨境申请
  公开号
发明名称
申请人
ALLERGAN INC ;
       The specification discloses compositions and methods for treating a soft tissue defect of an individual.

BTU COTTBUS
       The invention relates to a universal method for producing functional tissue. The subject matter of the invention includes the method for producing functional fusion tissue, the functional fusion tissue that can be obtained by means of said method, and the use of said functional fusion tissue, in particular as a pharmaceutical preparation, drug, transplant, implant, food, and test system. The invention relates in particular to the production of functional cartilage tissue and bone tissue from articular cartilage and bone.

GIELLEPI S P A
       The present invention relates to a composition for use in the treatment by topical administration of inflammatory diseases associated with tissue degeneration and/or tissue damage in humans or animals, comprising dehydrated avian egg albumen.

CENTRE NAT RECH SCIENT
       The present invention relates to an isolated cell having immunomodulatory potential, in which the expression and/or activity of periostin is modulated, or to the culture supernatant of said cell, for the use thereof as an immunosuppressive or immunostimulatory drug. The present invention also relates to periostin for the use thereof as an immunostimulatory drug or to a periostin inhibitor for the use thereof as an immunosuppressive drug.

UNIVERSITI KEBANGSAAN MALAYSIA
       An autologous tissue-engineered skin construct for use in various dermatological therapies and clinical applications, comprising cultured-expanded human keratinocyte cells and human fibroblast cells originated from a collagenase-digested and trypsinized skin sample, wherein the human keratinocyte cells and human fibroblast cells has been co-cultured and subcultured respectively with human serum-incorporated medium.

MANUKAMED LTD
       The present disclose relates to anti-inflammatory proteins/peptides, their uses, methods of preparation and methods of their detection. In particular, the invention relates to major royal jelly proteins modified by methyglyoxal and fragments thereof from a Leptospermum derived honey and royal jelly.

NIE PINGSHENG
       A Chinese medicine for treating breast cancer is prepared by using 1 to 3 parts by mass of common cephalanoplos herb, 1 to 3 parts by mass of pepper, 0.1 to 0.4 parts by mass of cinnamon, 0.1 to 0.2 parts by mass of musk, 2 to 5 parts by mass of sea buckthorn oil, and 1 to 3 parts by mass of selfheal.

NIE PINGSHENG
       A Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof. The Chinese medicine composition is prepared by using 5 to 10 parts by mass of xanthium sibiricum seed, 2 to 6 parts by mass of bark of peony root, 1 to 2 parts by mass of pilose antler and 0.5 to 2 parts by mass of minor bupleurum.

AGRONOMIQUE INST NAT RECH ;
       The invention relates to a method for isolating muscle-derived stem cells that can be used in cell therapy, said method comprising the steps of (i) dissociating cells from at least one muscle sample, (ii) plating the cells obtained at the end of step (i) on a non-coated cell container, (iii) isolating the cells present in the supernatant of the non-coated cell container obtained at the end of step (ii), (iv) plating the cells obtained at the end of step (iii) on a coated cell container, (v) isolating the cells present in the supernatant of the coated cell container obtained at the end of step (iv), (vi) repeating, or not, the steps (iii) and (iv) at least one or two times, (vii) plating and culturing the cells isolated from the supernatant of the coated cell container obtained at the end

  10  WO2013187194
MEDICAL CORP DOAI KAI ;
       [Problem] The present invention addresses the problem of providing a pharmaceutical composition useful for the treatment of bone diseases, which is of a different type from conventional pharmaceutical compositions used for the treatment of bone diseases. [Solution] The present invention relates to: a composition useful for the treatment of bone diseases; and a method for treating bone diseases using the composition. More specifically, the present invention relates to a pharmaceutical composition which can be used for treating a patient suffering from a bone disease, and which can be produced through the steps of: (1) culturing cells containing stem cells in a culture medium under bone differentiation-inducible conditions; (2) removing the cells from the culture medium to obtain a cultur

  11  WO2013187602
ESBIOTECH CO LTD
       The present invention relates to a pharmaceutical composition and a health functional food comprising a hard antler extract extracted at a high temperature of 130 DEG or higher. More particularly, the present invention relates to a pharmaceutical composition and a health functional food having enhanced quality, wherein the hard antler extract which is extracted at a high temperature of 130 DEG or higher contains greater amounts of growth hormone (GH), insulin-like growth factor (IGF-1), and erythropoietin (EPO) than hard antler extracts obtained by typical extraction methods, and also contains type-II collagen, so that the hard antler extract has the excellent effects of increasing immunity and growth hormone, improving hematogenous function and bone density, and suppressing rheumarthri

  12  WO2013188427
WOLF WILSON MFG CORP
       Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic applicat

  13  WO2013181746
NAT HEALTH RESEARCH INSTITUTES;
       This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.

  14  WO2013182207
UNIV KOEBENHAVN
       The invention relates to a product consisting of bovine colostrum for use in a method for minimal enteral nutrition for preterm infants, which product is given according to a specified dosage regime, while supplemental nutrients are supplied by total parenteral nutrition during at least the chief part of the treatment period. In a second aspect is provided the use of said product as minimal enteral nutrition for preterm infants according to the first aspect of the invention.

  15  WO2013183571
PUBLIC UNIVERSITY CORP NAGOYA CITY UNIVERSITY
       [Problem] To provide: a novel method for inducing the differentiation of an artificial pluripotent stem cell into a hepatocyte with high efficiency; and a use of the method. [Solution] The differentiation of an artificial pluripotent stem cell into a hepatocyte can be induced through: a step of differentiating the artificial pluripotent stem cell into an endoderm-like cell; and a step of differentiating the endoderm-like cell produced in the preceding step into a hepatocyte-like cell, in which at least a part of the culturing of the endoderm-like cell is carried out in the presence of a histone deacetylase inhibitor and/or under oxidative stress-applied conditions.

  16  WO2013183774
SUMITOMO CHEMICAL CO ;
       Provided are a method for producing cell aggregates containing a ciliary marginal zone-like structure, etc., said method being characterized by comprising a step for culturing cell aggregates containing a retinal tissue, in said retinal tissue Chx10-positive cells existing at a ratio of 20% or greater, in a serum free medium or a serum medium containing a Wnt signaling pathway agonist only for a period until RPE65 gene-expressing cells appear, and then culturing "cell aggregates in which no RPE65 gene-expressing cell appears" in a serum free medium or a serum medium containing no Wnt signaling pathway agonist. According to the present invention, a ciliary marginal zone-like structure can be produced at a high efficiency.

  17  WO2013184011
GDANSKI UNIV MEDYCZNY
       The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains - Treg cells CD3(+)CD4(+)CD25(high)CD127(-). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.

  18  WO2013184527
CAPRICOR INC
       The present disclosure relates generally to methods for the increased processing of tissue for the generation of cardiac stem cells, wherein the stem cells are suitable for use in cardiac stem cell therapy. In particular, several embodiments relate to the processing of allogeneic donor cardiac tissue for the generation of multiple patient doses of cardiac stem cells.

  19  WO2013184966
UNIV CENTRAL FLORIDA RES FOUND ;
       The present invention is directed to methods and systems directed to altering the differentiation of a cell, more particularly to biasing a potent cell, such as a mesenchymal stem cell, by contacting such cell with a protein having properties of bone morphogenic protein-4. The contacting may be achieved via genetic modification, and the resulting cell may be or have characteristics of a pre-adipocyte. Pre-adipocyte cells so-obtained, and their progeny, may be used for various purposes, including in cosmetic and other surgical therapies and treatments.

  20  WO2013181326
UNIV CORNELL
       This disclosure is directed to methods for reproducibly generating substantial amounts of endothelial cells from amniotic cells. The endothelial cells generated in accordance with the present methodology, as well as therapeutic methods utilizing these cells, are also disclosed.

  21  WO2013181424
NEUROTECH USA INC
       The invention provides cryopreserved encapsulated cell therapy devices that are capable of delivering biologically active molecules as well as methods of using these devices.

  22  WO2013181641
SALK INST FOR BIOLOGICAL STUDI
       Provided herein are, inter alia, methods of forming, identifying and isolating totipotent stem cells. The methods and compositions provided herein are particularly useful for reprogramming somatic cells and tissue regeneration. Further provided are totipotent stem cells formed using the methods provided herein as well as non-totipotent cells capable of forming totipotent stem cells.

  23  WO2013181642
NEOSTEM INC ;
       The present invention relates to use of very small embryonic-like (VSEL) stem cells in therapies for ocular disease involving retinal degeneration or dysfunction. The invention also included pharmaceutical compositions made with VSELs which may be used to restore lost vision or reduce or halt vision loss due to diseases or disorders of the retina, or other diseases or retinal injuries that would benefit from stem cell replacement therapy.

  24  WO2013155488
HARVARD BIOSCIENCE INC
       According to some aspects, tissue scaffolds are provided that comprise one or more types of nanofibers. In some embodiments, one or more design features are incorporated into a tissue scaffold (e.g., an electrospun tissue scaffold) to control the elasticity of the scaffold in at least one direction, making the scaffold suitable for withstanding mechanical forces when implanted in the body of a subject

  25  WO2013174769
BOEHRINGER INGELHEIM INT
       The invention relates to new keratinocytes which may be cultured in vitro and the use thereof for preparing a product which can be used to treat acute and chronic wounds, in combination with a DPP-4 inhibitor.

  26  WO2013175759
NAT UNIVERSITY CORP ASAHIKAWA MEDICAL UNIVERSITY
       The present invention pertains to: a technique for promoting stabilization and maturation of new blood vessels, and for safely and simply inducing the differentiation of cells that bring about ischemia and tissue repair from mononuclear cells; and a cell group obtained according to such a technique. The cells of the present invention: induce differentiation of mononuclear cells by using a medium (in particular, a serum-free medium) containing VEGF, bFGF and a clinically-available cMpl agonist for incubation; and can be adjusted by recovering a group of cells in which CD11b is expressed.

  27  WO2013176140
ASAHI KASEI MEDICAL CO LTD
       The purpose of the present invention is to provide a high-concentration protein solution production method for producing a protein-rich solution by concentrating a dilute protein such as ascetic fluid, said method enabling the production of a protein-rich solution having a high protein concentration without undergoing the deterioration in concentration efficiency caused by clogging or without employing an additional treatment time such as a time for an additional concentration step. The present invention is a method for producing a high-concentration protein solution, which comprises a first step of allowing a low-concentration protein solution stored in a storage container to pass through a polysulfone-based hollow-fiber-membrane-type filter for ascetic fluid concentration use, which is

  28  WO2013176197
UNIV TOKYO
       [Problem] To obtain a very high frequency of T cells having the same TCR gene reconstitution pattern as the original human T cells in CD8 single-positive cells or CD4 single-positive cells obtained by redifferentiation from human T cells having antigen specificity via iPS cells. [Solution] A method for producing human CD8 single-positive cells or CD4 single-positive cells having antigen specificity, wherein the method comprises a step for differentiating to CD4/CD8 double-negative cells iPS cells induced from human T cells, a step for stimulating the T cell receptor of the CD4/CD8 double-negative cells, and a step for differentiating to CD8 single-positive or CD4 single-positive cells the CD4/CD8 double-negative cells whose T-cell receptor has been stimulated.

  29  WO2013176322
BIO SPECTRUM INC ;
       The present invention relates to a composition containing phloridzin as a novel bioactive substance, which composition is applicable to a cell culture composition for promoting cell proliferation and providing a substitute for an animal serum, and a composition for improving skin conditions, such as for alleviating inflammatory skin diseases, improving skin wrinkles, suppressing skin aging, improving skin elasticity, and helping regeneration of wounds or skin.

  30  WO2013176351
NAT UNIV GYEONGSANG IACF
       The present invention relates to a composition comprising an extract of a mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of Undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production. However, it is assumed that the composition has the effects of suppressing inflammation as well as regenerating skin.

  31  WO2013149211
UNIV SOUTHERN CALIFORNIA
       Mesenchymal Stem Cells (MSCs), including bone marrow-derived MSCs (BMMSCs) expressing Fas and FasL, and secreting MCP-1 are disclosed. Also disclosed are methods for upregulating regulatory T cells in a subject by administering MSCs, including BMMSCs. Also disclosed are methods for treating systemic sclerosis or colitis in a subject by administering MSCs, including BMMSCs.

  32  WO2013171752
MINOVIA THERAPEUTICS LTD
       The present invention relates to compositions and methods of inducing angiogenesis and methods of treating a pathology that would benefit from angiogenesis by use of a composition comprising partially purified intact mitochondria and/or ruptured mitochondria derived therefrom.

  33  WO2013172087
TAKEDA SURVEY DESIGN CO LTD ;
       [Problem] To provide a composition provided with nitric oxide production-inhibiting activity substantially free of cytotoxicity. [Solution] The present invention is characterized by comprising either dried fish meat of Dojo loach and of a fish of the same aspect of habitation as Dojo loach, or a processed product of said dried fish meat, as an active ingredient.

  34  WO2013172525
COSEEDBIOPARM CO LTD ;
       The present invention relates to a multifunctional cosmetic composition containing pieces or an extract from fish eyes as an active ingredient, which has good skin whitening effects and good skin resiliency improving effects, and has good skin moisturizing effects and cell activation effects, so as to exhibit excellent skin-regenerating and wound healing effects as well as excellent irritation relief effects. Also, the present invention relates to a composition for preventing and treating arthritis, which includes pieces or an extract from fish eyes as an active ingredient. The composition of the present invention promotes immune tolerance in the intestinal immune system without having any side effects so as to prevent and treat arthritis by effectively controlling autoimmune reactions an

  35  WO2013172724
KOWALCZYK ZBIGNIEW
       The present invention relates to the method for treating obesity and overweight and gastro-oesophageal reflux disease (GERD). According to the invention the method for treating obesity and overweight and gastro-oesophageal reflux disease lies in the fact that the stem and regenerative cells extracted from adipose tissue (ADRC - Adipose Derived Regenerative Cells) are injected into the submucosa tissue or muscle near the gastric cardia and fundus. The isolated ADRC cells are given via endoscopy or surgical procedures, open or laparoscopic. The isolated ADRC cells are enriched with fat graft in the amount of at least 5 ml and not more than 25 ml. The method is complementary to other bariatric procedures reducing the size of the stomach - such as adjustable gastric band, gastric sleeve parti

  36  WO2013172793
AGENCY SCIENCE TECH & RES ;
       We describe a method of cell culture of an umbilical mesenchymal stem cell (MSC). The method comprises the steps of providing an umbilical mesenchymal stem cell (MSC) and culturing the umbilical mesenchymal stem cell in a cell culture medium under hypoxic conditions. The umbilical mesenchymal stem cell may be transformed with an oncogene such as c-myc. Conditioned media and exosomes obtained from the umbilical mesenchymal stem cell may be used for therapy.

  37  WO2013172944
SANBIO INC ;
       Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous Notch intracellular domain. The transplanted cells form a pathway along which endogenous neurogenic cells proliferate and migrate from the subventricular zone to the site of injury.

  38  WO2013173076
UNIV SOUTHERN CALIFORNIA ;
       The present invention is directed to generating suppressor cells by treating naive T cells with a suppressor-inducing composition such as anti-CD3, anti-CD28, IL-2, TGF-beta, or some combination thereof. Such suppressor cells are administered to patients to prevent or treat immune disorders and are allogeneic to the patient.

  39  WO2013173376
DEPUY SYNTHES PRODUCTS LLC
       This invention encompasses methods, pharmaceutical compositions, and kits, which utilize umbilical cord tissue-derived cells, for modulating (e.g. reducing) the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury. The invention also encompasses methods, pharmaceutical compositions, and kits, which utilize umbilical cord tissue-derived cells, for inhibiting the production of pro-inflammatory mediators involved in the pathology of a lung disease, disorder, and/or injury in a patient having the lung disease, disorder, and/or injury utilizing umbilical cord tissue-derived cells. In one embodiment, the umbilical cord tissue-derived cells are isolated from human umbilical cord

  40  WO2013173778
CRITICAL CARE DIAGNOSTICS INC ;
       Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in

  41  WO2013166766
BIOZEN PHARMACEUTICAL CO LTD ;
       An external preparation for prophylaxis and treatment of skin inflammation caused by computer and mobile phone radiation. The active ingredient of the external preparation is propolis, and the propolis accounts for 0.1-60% (W/W) of the external preparation. The preparation may be a gel, emulsion, cream, micro emulsion, or liquid preparation, and is mainly targeted at skin inflammation caused by computer and mobile phone radiation.

  42  WO2013167136
HERLEV HOSPITAL
       The present invention relates to a method for improving the clinical efficacy of adoptive cell therapy with Interferon-gamma (IFN-gamma). The invention further relates to Interferon gamma for use as a medicament in a method of promoting regression of a cancer in a mammal, wherein said method comprises autologous adoptive cell therapy of tumour-infiltrating lymphocytes. Also provided is a method of treating a mammal with a recurrent cancer, said mammal having previously received immunotherapy.

  43  WO2013168402
OTSUKA PHARMA CO LTD ;
       This invention addresses the problem of providing: a mammalian cell suspension capable of preventing the formation of pulmonary embolisms when mammalian stem cells or other mammalian cells are administered intravenously; or a prophylactic agent against the formation of pulmonary embolisms when mammalian cells are administered intravenously. This invention is characterized by the suspension of mammalian stem cells or other mammalian cells in a physiological aqueous solution including as an effective component thereof dextran, a derivative thereof, or a salt of either, and the preparation of the mammalian cell suspension for the prevention of pulmonary embolism formation when administering mammalian cells intravenously, said suspension containing as an effective component thereof mammalian

  44  WO2013168403
OTSUKA PHARMA CO LTD
       This invention addresses the problem of providing: a mammalian cell suspension capable of preventing the formation of pulmonary embolisms when mammalian stem cells or other mammalian cells are administered intravenously; or a prophylactic agent against the formation of pulmonary embolisms when mammalian cells are administered intravenously. This invention is characterized by the suspension of mammalian stem cells or other mammalian cells in a physiological aqueous solution including as an effective component thereof trehalose, a derivative thereof, or a salt of either, and the preparation of a mammalian cell suspension for the prevention of pulmonary embolism formation when administering mammalian cells intravenously, said suspension containing as an effective component thereof: mammalia

  45  WO2013168978
UNIV KOREA RES & BUS FOUND
       The present invention relates to a method for inducing and proliferating natural killer cells derived from peripheral blood mononuclear cells, the method comprising co-culturing, as vegetative cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or cytokines, thereby making it possible to significantly improve the efficiency and efficacy of using the natural killer cells for the prevention and treatment of cancer.

  46  WO2013169202
BIOMATCELL AB
       The present invention relates to a method for inducing and/or promoting osteogenic differentiation using extracellular vesicles and the use thereof.

  47  WO2013134248
FIBROCELL TECHNOLOGIES INC
       Personalized skin-specific topical formulations containing conditioned medium obtained from cultures of fibroblasts has been developed. Unlike other topical formulations, these formulations are specific for the recipient-skin type specific, and conditioned medium is obtained from a subject with desired skin characteristics. For example, since African American skin is known to wrinkle less and later than Caucasian skin, conditioned medium may be obtained from African American skin for application to pale skin. In another embodiment, the fibroblasts are obtained from young skin for administration to older skin. In still another embodiment, the fibroblasts are obtained from skin that does not suffer from acne or discoloration, for application to skin that is prone to acne or discoloration.;

  48  WO2013163744
DO PAUL PHUONG ;
       A nutritional composition is provided herein for optimizing muscle performance during exercise and for enhancing muscle cell repair and recovery following the cessation of exercise, comprising: a) about 18% to about 23% by weight, e.g. about 19% to about 21%), of whey protein, e.g. whey protein isolate; b) about 65% to about 70% by weight, e.g. about 67% to about 69%, of a superfruit blend, a concentrated fruit juice and a sweetener, e.g., honey; and c) about 10% to about 15% by weight, e.g., about 11% to about 13 %, of a vegetable oil, e.g., olive oil, e,g., extra virgin olive oil, virgin olive oil, cold pressed olive oil.

  49  WO2013164289
IMCYSE SA ;
       The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory T cells in vitro or in vivo. Cells loaded with apoptotic bodies/cells and regulatory T cells are obtainable by inducing apoptosis of antigen-presenting cells by cytolytic CD4+ T cells. The cells are used for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are the use of antigen-specific regulatory T cells for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are pop

  50  WO2013165120
UNIV INJE IND ACAD COOPERATION
       The present invention relates to a method for culturing neural crest stem cells derived from peripheral nerves, to a neural crest stem cell culture cultured by the method, to a method for differentiating the neural crest stem cells, and to a cell therapeutic agent and treatment agent for diseases of the nervous system which involve the neural crest stem cells, wherein the method for culturing neural crest stem cells comprises the steps of: culturing a fragment of a peripheral nerve after inserting the latter into a hydrogel; and collecting neural crest stem cells, which have migrated into the hydrogel and proliferated, from the fragment of the peripheral nerve by breaking down only the hydrogel. The neural crest stem cells cultured by the culturing method have excellent proliferation cap

  检索记录:  2728  总页数:  55  当前页码: 1      每页条数:  50 100 200   9 3 4 :      返回

日本专利